Progress in protein tyrosine phosphates (PTPs) related to insulin signaling pathway

Abstract

Abstract: Protein tyrosine phosphates (PTPs) are key regulators of the insulin receptor signal transduction pathway. Insulin signaling is tightly regulated by the balance of IR tyrosine phosphorylation and dephosphorylating. Several PTPs expressed in the major human insulin target tissues or cells and could attenuate insulin action by dephosphorylating the IR. Inhibiting several PTPs would prolong insulin signaling and facilitate glucose uptake and decrease blood glucose. Inhibitors of several PTPs are predicted to be the novel drug targets for type 2 diabetes and obesity treatment.

Key words: Protein tyrosine phosphates, Type 2 diabetes, Insulin signal, Protein tyrosine phosphates inhibitor

CLC Number:

R587

DONG Min, LIU Zhao-qian. Progress in protein tyrosine phosphates (PTPs) related to insulin signaling pathway[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2011, 16(10): 1179-1185.

References

[1] Tonks NK. Protein tyrosine phosphates: from genes, to function, to disease[J]. Nat Rev Mol Cell Biol, 2006, 7(11): 833-846.
[2] Taniguchi CM, Emanuelli B, Kahn CR. Critical nodes in signaling pathways: insights into insulin action[J]. Nat Rev Mol Cell Biol, 2006, 7(2): 85-96.
[3] Johnson TO, Ermolieff J, Jirousek MR. Protein tyrosine phosphates 1B inhibitors for diabetes[J]. Nat Rev Drug Discov, 2002, 1(9): 696-709.
[4] White MF, Kahn CR. The insulin signaling system[J]. J Biol Chem, 1994, 269(1): 1-4.
[5] Ostman A, Hellberg C, Bohmer FD. Protein tyrosine phosphates and cancer[J]. Nat Rev Cancer, 2006,6(4):307-320.
[6] Alonso A, Sasin J, Bottini N, et al. Protein tyrosine phosphates in the human genome[J]. Cell, 2004, 117(6):699-711.
[7] Elchebly M, Cheng A,Tremblay ML. Modulation of insulin signaling by protein tyrosine phosphates[J]. J Mol Med, 2000, 78(9): 473-482.
[8] Goldstein BJ. Protein-tyrosine phosphates 1B (PTP1B): a novel therapeutic target for type 2 diabetes mellitus, obesity and related states of insulin resistance[J]. Immune Endocr Metabol Disord, 2001, 1(3): 265-275.
[9] Buist A, Zhang YL, Keng YF, et al. Restoration of potent protein-tyrosine phosphates activity into the membrane-distal domain of receptor protein-tyrosine phosphates alpha[J]. Biochemistry, 1999, 38(3): 914-922.
[10] Groen A, Lemeer S, van der Wijk T, et al. Differential oxidation of protein-tyrosine phosphates[J]. J Biol Chem, 2005, 280(11): 10298-10304.
[11] Meng TC, Fukada T, Tonks NK. Reversible oxidation and inactivation of protein tyrosine phosphates in vivo[J]. Mol Cell, 2002, 9(2): 387-399.
[12] Wishart MJ, Dixon JE. Gathering STYX: phosphatase-like form predicts functions for unique protein-interaction domains[J]. Trends Biochem Sci, 1998, 23(8): 301-306.
[13] Robinson FL, Dixon JE. The phosphoinositide-3-phosphatase MTMR2 associates with MTMR13,a membrane-associated pseudo-phosphates also mutated in type 4B Charcot-Marie-Tooth disease[J]. J Biol Chem, 2005, 280(36): 31699-31707.
[14] Kim SA, Vacratsis PO, Firestein R, et al. Regulation of myotubularin-related (MTMR)2 Phosphatidylinositol phosphates by MTMR5, a catalytically inactive phosphates[J]. Proc Natl Acad Sci USA, 2003, 100(8): 4492-4497.
[15] Kasibhatla B, Wos J, Peters KJ. Targeting protein tyrosine phosphates to enhance insulin action for the potential treatment for diabetes[J]. Curr Opin Investig Drugs, 2007, 8 (10): 805-813.
[16] Ahmad F, Goldstein BJ. Functional association between the insulin receptor and the Tran membrane protein-tyrosine phosphates LAR in intact cells[J]. J Biol Chem, 1997, 272(1): 448-457.
[17] Li PM, Zhang WR, Goldstein BJ. Suppression of insulin receptor activation by over expression of the protein tyrosine phosphates LAR in hepaticas cells[J]. Cell Signal, 1996, 8(7): 467-473.
[18] Kulas DT, Goldstein BJ, Mooney RA. The transmembrane protein-tyrosine phosphates LAR modulates signaling by multiple receptor tyrosine kinases[J]. J Biol Chem, 1996, 271(2): 748-754.
[19] Ren JM, Li PM, Zhang WR, et al. Transgenic mice de?cient in the LAR protein-tyrosine phosphates exhibit profound defects in glucose homeostasis[J]. Diabetes, 47(3): 493-497.
[20] Zabolotny JM, Kim YB, Peroni OD, et al. Over expression of the LAR (leukocyte antigen-related) protein-tyrosine phosphates in muscle causes insulin resistance[J]. Proc Natl Acad Sci USA, 2001, 98(9): 5187-5192.
[21] Moller NP, Moller KB, Lammers R, et al. Selective down-regulation of the insulin receptor signal by protein-tyrosine phosphates alpha and epsilon[J]. J Biol Chem, 1995, 270(39): 23126-23131.
[22] Cong LN, Chen H, Li Y,et al. Over expression of protein tyrosine phosphates-alpha (PTP-alpha) but not PTP-kappa inhibits translocation of GLUT4 in rat adipose cells[J]. Biochem Biophys Res Commun, 1999, 255(2): 200-207.
[23] Arnott CH, Sale EM, Miller J, et al. Use of an antisense strategy to dissect the signaling role of protein-tyrosine phosphates alpha[J]. J Biol Chem, 1999, 274(37): 26105-26112.
[24] Su J, Muranjan M, Sap J. Receptor protein tyrosine phosphates alpha activates Src-family kinas sand controls integrant-mediated responses in fibroblasts[J]. Curr Biol,1999, 9(10): 505-511.
[25] Le HT, Ponniah S, Pallen CJ. Insulin signaling and glucose homeostasis in mice lacking protein tyrosine phosphates alpha[J]. Biochem Biophys Res Commun, 2004, 314(2):321-329.
[26] Rocchi S, Tartare-Deckert S, Sawka-Verhelle D, et al. Interaction of SH2-containing protein tyrosine phosphates 2 with the insulin receptor and the insulin-like growth factor-I receptor: studies of the domains involved using the yeast two-hybrid system[J]. Endocrinology, 1996, 137(11): 4944-4952.
[27] Tenev T, Keilhack H, Tomic S ,et al. Both SH2 domains are involved in interaction of SHP-1 with the epidermal growth factor receptor but cannot confer receptor-directed activity to SHP-1/SHP-2chimera[J]. J Biol Chem, 1997, 272(9): 5966-5973.
[28] Hayashi K, Shibata K, Morita T, et al. Insulin receptor substrate-1/SHP-2 interaction, a phenotype dependent switching machinery of insulin-like growth factor-I signaling in vascular smooth muscle cells[J]. J Biol Chem, 2004, 279(39): 40807-40818.
[29] Milarski KL, Saltiel AR. Expression of catalytically inactive Spy phosphates in 3T3 cells blocks stimulation of mitogen-activated protein kinase by insulin[J]. J Biol Chem, 1994, 269(33): 21239-21243.
[30] Clemmons DR, Maile LA. Mini review: integral membrane proteins that function coordinately with the Insulin-like Growth Factor 1 Receptor to regulate intracellular signaling[J]. Endocrinology, 2003, 144(5): 1664-1670.
[31] Tartaglia M, Gelb BD. Noonan syndrome and related disorders: genetics and pathogenesis[J]. Annu Rev Genomics Hum Genet,2005, 6: 45-68.
[32] Mohi MG, Neel BG. The role of Shp2 (PTPN11) in cancer[J]. Curr Opin Genet Dev, 2007, 17(1): 23-30.
[33] Tonks NK, Diltz CD, Fischer EH. Purification of the major protein tyrosine phosphates of human placenta[J]. J Biol Chem, 1988, 263(14): 6722-6730.
[34] Frangioni JV, Beahm PH, Shifrin V, et al. The non transmembrane tyrosine phosphates PTP-1B localizes to the endoplasmic reticulum via its 35 amino acid C-terminal sequence[J]. Cell, 1992, 68(3):545-560.
[35] Brown-Shimer S, Johnson KA, Lawrence JB, et al. Molecular cloning and chromosome mapping of the human gene encoding protein tyrosyl phosphates 1B[J]. Proc Natl Acad Sci USA, 1990,87(13): 5148-5152.
[36] Echwald SM, Bach H, Vestergaard H, et al. A P387L variant in protein tyrosinphosph e atase-1B (PTP1B) is associated with type 2 diabetes and impaired serine phosphorylation of PTP-1B in vitro[J]. Diabetes, 2002, 51(1): 1-6.
[37] Mok A, Cao H, Zinman B, et al. A single nucleotide polymorphism in protein tyrosine phosphates PTP-1B is associated with protection from diabetes or impaired glucose tolerance in Oji-Cree[J]. J Clin Endocrinol Metab, 2002, 87(2): 724-727.
[38] Di Paola R, Frittitta L, Miscio G, et al. A variation in 3' UTR of hPTP1B increases gene expression and associates with insulin resistance[J]. Am J Hum Genet, 2002, 70(3): 806-812.
[39] Bento JL, Palmer ND, Mychaleckyj J, et al. Association of protein tyrosine phosphates 1B gene polymorphisms with type 2 diabetes[J]. Diabetes, 2004, 53(11): 3007-3012.
[40] Florez JC, Agapakis CM, Burtt NP, et al. Association testing of the protein tyrosine phosphates 1B gene (PTPN1) with type 2 diabetes in 7,883 people[J]. Diabetes, 2005, 54(6): 1884-1891.
[41] Traurig M, Hanson RL, Kobes S, et al. Protein tyrosine phosphates 1B is not a major susceptibility gene for type 2 diabetes mellitus or obesity among Pima Indians[J]. Diabetologia, 2007, 50(5):985-989.
[42] Cheyssac C, Lecoeur C, Dechaume A, et al. Analysis of common PTPN1 gene variants in type 2 diabetes, obesity and associated phenotypes in the French population[J]. BMC Med Genet, 2006, 7:(44).
[43] Seely BL, Staubs PA, Reichart DR, et al. Protein tyrosine phosphates 1B interacts with the activate insulin receptor[J]. Diabetes, 1996, 45(10): 1379-1385.
[44] Bandyopadhyay D, Kusari A, Kenner KA, et al. Protein-tyrosine phosphates 1B complexes with the insulin receptor in vivo and is tyrosine-phosphorylated in the presence of insulin[J]. J Biol Chem, 1997, 272(3): 1639-1645.
[45] Cicirelli MF, Tonks NK, Diltz CD,et al. Microinjection of a protein-tyrosine-phosphate inhibits insulin action in Xenopus oocytes[J]. Proc Natl Acad Sci USA, 1990, 87(14): 5514-5518.
[46] Fukuda S, Ohta T, Sakata S, et al. Pharmacological profiles of a novel protein tyrosine phosphatase 1B inhibitor, JTT-551[J]. Diabetes Obes Metab,2010, 12(4):299-306.
[47] Koren S, Fantus IG. Inhibition of the protein tyrosine phosphatase PTP1B: potential therapy for obesity, insulin[J]. Best Pract Res Clin Endocrinol Metab, 2007, 21(4):621-640.